Yahoo Search Búsqueda en la Web

Resultado de búsqueda

  1. Hace 5 días · Beckman Coulter es ahora un distribuidor autorizado del ensayo MeMed BV, una prueba de inmunoensayo rápido que puede diferenciar entre infecciones bacterianas y virales, y MeMed Key, un analizador de inmunoensayo compacto que está autorizado para ejecutar el ensayo MeMed BV en Estados Unidos y Europa.

  2. Hace 5 días · BREA, CALIF., May 29, 2024 — Beckman Coulter, a global leader in clinical diagnostics, today announced U.S. Food and Drug Administration clearance of its Access NT-proBNP (N-terminal Pro B-type Natriuretic Peptide) assay for the assessment of heart failure in less than 11 minutes on the Beckman Coulter DxI 9000 Immunoassay Analyzer*.

  3. Hace 5 días · BREA, Calif., May 29, 2024 /PRNewswire/ -- Beckman Coulter, a global leader in clinical diagnostics, today announced U.S. Food and Drug Administration clearance of its Access NT-proBNP...

  4. Hace 5 días · Beckman Coulter, a global leader in clinical diagnostics, today announced U.S. Food and Drug Administration clearance of its Access NT-proBNP (N-terminal Pro B-type Natriuretic Peptide) assay for ...

  5. Hace 4 días · Beckman Coulter, a clinical diagnostics company of Danaher Corporation, has received the US Food and Drug Administration approval for its new heart failure assay, Access NT-proBNP. The Access NT-proBNP (N-terminal Pro B-type Natriuretic Peptide) assay is designed to run on the company’s DxI 9000 Immunoassay Analyser and detects heart failure within 11 minutes.

  6. Hace 5 días · Beckman Coulter Secures FDA Clearance for Heart Failure Assay on DxI 9000 Immunoassay Analyzer. Published: May 29, 2024. New Access NT-proBNP Assay Detects Heart Failure Biomarker in Less than 11 Minutes. Patient Results Evaluated Within Context of Clinically Relevant.

  7. Hace 4 días · Beckman Coulter, a leading name in clinical diagnostics, has recently gained approval from the U.S. Food and Drug Administration for its Access NT-proBNP (N-terminal Pro B-type Natriuretic Peptide) assay. This advancement enables the swift assessment of heart failure in under 11 minutes using the Beckman Coulter DxI 9000 Immunoassay Analyzer*.

  1. Otras búsquedas realizadas